This page is updated frequently with new Proliferation-related patent applications.
|Near-infrared light-activated proteins|
Methods and constructs are provided for controlling processes in live animals, plants or microbes via genetically engineered near-infrared light-activated or light-inactivated proteins including chimeras including the photosensory modules of bacteriohytochromes and output modules that possess enzymatic activity and/or ability to bind to dna, rna, protein, or small molecules. Dna encoding these proteins are introduced as genes into live animals, plants or microbes, where their activities can be turned on by near-infrared light, controlled by the intensity of light, and turned off by near-infrared light of a different wavelength than the activating light.
University Of Wyoming
|Antagonist anti-cd40 monoclonal antibodies and methods for their use|
Compositions and methods of therapy for treating diseases mediated by stimulation of cd40 signaling on cd40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-cd40 antibody or antigen-binding fragment thereof to a patient in need thereof.
Novartis Vaccines And Diagnostics, Inc.
|Anti-il1rap antibodies and their use for treating human|
The present invention provides agents comprising or consisting of a binding moiety with specificity for interleukin-1 receptor accessory protein (il1rap) for use in inducing cell death and/or inhibiting the growth and/or proliferation of cells associated with a solid tumour, wherein the cells express il1rap. A related aspect of the invention provides agents comprising or consisting of a binding moiety with specificity for interleukin-1 receptor accessory protein (il1rap) for use in detecting pathological cells associated with a solid tumour, wherein the cells express il1rap.
|Regulatable chimeric antigen receptor|
Provided are compositions and methods relating to regulatable chimeric antigen receptors (rcars), natural killer cell receptor cars (nkr-cars), and regulatable nkr-cars (rnkr-cars), where the intracellular signaling or proliferation of the rcar or rnkr-car can be controlled to optimize the use of an rcar/nkr-car- or rnkr-car-expressing cell to provide an immune response. Cells can be engineered to express a rnkr-car or to express a rcar and a nkr-car (e.g., inhibitory nkr-car).
The Trustees Of The University Of Pennsylvania
|Anti-il-17 antibodies, producing same and using same|
The present invention relates to the field of medicine, and specifically to the field of monoclonal antibodies against human il-17. More specifically, the invention relates to monoclonal antibodies/antagonists of il-17a, which bind with high affinity to an il-17 epitope, wherein the antibodies contain amino acid substitutions in hypervariable regions of heavy and light chains.
Closed Joint Stock Company "biocad"
|3,4-dihydroquinazoline derivative and combination comprising the same|
A 3,4-dihydroquinazoline derivative or a pharmaceutically acceptable salt thereof and a composition containing the same are provided. The 3,4-dihydroquinazoline derivative or a pharmaceutically acceptable salt thereof show activities of blocking an intracellular influx of calcium ions acting as a secondary signal essential to the proliferation and growth of cancer cells, thereby inducing the cell cycle arrest of cancer cells, and eventually reinforcing the efficacy of existing anti-cancer drugs.
University-industry Cooperation Group Of Kyung Hee University
|Gene delivery stent using titanium oxide thin film coating and fabricating the same|
The present invention relates to a gene delivery stent using titanium oxide thin film coating and a method for fabricating the gene delivery stent. The gene delivery stent according to the present invention may be loaded with a drug having anti-inflammatory and anti-thrombotic effects and simultaneously deliver a gene capable of inhibiting proliferation of vascular smooth muscle cells.
Chonnam National University Hospital
|Dendrimeric platform for controlled release of drugs|
A multifunctional molecular platform is provided, for covalent binding of two or more therapeutic or diagnostic agents, and for their sequential release in a biological environment near desired target sites. The platform is used in the preparation of pharmaceutical compositions for treating abnormal cell proliferation, infections, and inflammation..
Ariel-university Research And Development Company Ltd.
|Tyrosine derivatives and compositions comprising them|
Compositions and kits comprising a tyrosine hydroxylase inhibitor and an anticancer agent that is chemically bonded to, or physically associated with, the tyrosine hydroxylase inhibitor are provided. Also provided are methods for reducing cell proliferation in a subject comprising administering to a subject in need thereof a composition comprising a tyrosine hydroxylase inhibitor and an anticancer agent that is chemically bonded to, or physically associated with, the tyrosine hydroxylase inhibitor..
|Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders|
Thyroid hormone antagonists and their nanoparticle formulations (nanotetrac™ or nanotriac™) act at a cell surface receptor to block angiogenesis and tumor cell proliferation. The complex anti-angiogenic performs actions on specific cytokines and chemokines.
Compositions and methods for modulating the immune system
A novel class of embryo derived peptides are described (preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a th2 type cytokine bias, in addition pif enhance endometrial receptivity by increasing adhesion molecules expression. Pif biological activity appears to be exerted by specific binding to inducible receptors present on the several white cell lineages.
Cancer stem cell proliferation inhibitor
The present invention aims to provide a growth inhibitor for cancer stem cells resistant to existing anticancer drug therapies, which growth inhibitor acts on the cells through growth inhibition and apoptosis. The growth inhibitor for cancer stem cells contains a retinoid agonist, preferably tamibarotene, alone or in combination with a rexinoid agonist, preferably bexarotene, as an effective component(s).
Tmrc Co., Ltd.
Compositions and methods for modified dendrimer nanoparticle delivery
Compositions and methods for modified dendrimer nanoparticle (“mdnp”) delivery of therapeutic, prophylactic and/or diagnostic agent such as large reprna molecules to the cells of a subject have been developed. Mdnps efficiently drive proliferation of antigen-specific t cells against intracellular antigen, and potentiate antigen-specific antibody responses.
Whitehead Institute For Biomedical Research
Bio-adhesive gels and methods of use
A gel composition that forms a three dimensional gel microenvironment that is formed of an adhesive protein, a maleimide-functionalized poly alkylene oxide, a linking agent and a nanoparticle, the components forming an interpenetrating network that exhibits improved mechanical and biochemical properties, as well as creates a favorable microenvironment for cellular growth and proliferation. The gel composition also creates a favorable microenvironment for testing various agents on normal or diseased cells, including chemotherapeutic agents on cancer cells or other diseased cells..
Melk regulation for the treatment of breast cancer
Methods for inhibiting growth or proliferation of breast cancer cells are provided. The methods include administering to a subject in need thereof in an amount that is effective to inhibit growth or proliferation of the breast cancer cells a melk inhibitor, wherein the breast cancer cells are estrogen receptor (er) negative.
Ex vivo proliferation of epithelial cells
The technology relates in part to methods and compositions for ex vivo proliferation and expansion of epithelial cells.. .
Cell determination device, cell determination method, and cell determination program
Disclosed are a cell determination device, a cell determination method, and a non-transitory computer readable recording medium recorded with a cell determination program capable of objectively determining a state of a cell with high accuracy. The cell determination device includes: a cell information acquisition unit 31 that acquires information relating to a proliferation rate of a cell and information relating to a movement distance of the cell per unit time based on plural cell images obtained by imaging the cell in a time series manner; and a determination unit 32 that determines a state of the cell based on the information relating to the proliferation rate and the information relating to the movement distance..
Methods of selective cell attachment/detachment, cell patternization and cell harvesting by means of near infrared rays
The present invention relates to a method for selective cell attachment/detachment, cell patternization and cell harvesting by means of near infrared rays. More particularly, conducting polymers or metal oxides having exothermic characteristics upon irradiation of near infrared light is used as a cell culture scaffold, thus selectively attaching/detaching cells without an enzyme treatment.
Industry-academic Cooperation Foundation, Yonsei University
Cell culture method and cell culture device
A cell culture method conducted by supplying a culture medium together with cells to a container (1), an upward movement step in which the container is moved upward to a position higher than the initial position and a downward movement step in which the container that has been moved upward is returned to the initial position, and vibration is applied to the container that has been returned to the original position are repeated, whereby a content liquid in the container is stirred. As a result, a good culture environment is maintained by conducting stirring such that distribution of cells and concentration of components of a culture medium in a content liquid become uniform, while reducing damage on cells by shear stress, and adherence of cells to the inner wall or excessive agglomeration is suppressed by stirring, whereby proliferation of cells can be promoted..
Toyo Seikan Group Holdings, Ltd.
Antibodies against the ectodomain of erbb3 and uses thereof
The present invention provides a novel class of antibodies and antigen binding fragments thereof that bind the extracellular domain of erbb3 receptor and inhibit various erbb3 functions. For example, the antibodies and antigen binding fragments described herein are capable of binding to the receptor designated erbb3 and inhibiting egf-like ligand mediated phosphorylation of the receptor.
Merrimack Pharmaceuticals, Inc.
Engineered antibody-interferon mutant fusion molecules
The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to fusion molecule constructs wherein a tumor associated antigen (taa) antibody (ab) serves as a targeting moiety to selectively deliver a cytokine to a tumor cell for purposes of killing or inhibiting the growth or proliferation of said tumor cell.
The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds.
Asana Biosciences, Llc
Extracellular matrix compositions for the treatment of cancer
The present invention is directed to methods of inhibiting cancer cell growth or proliferation by contacting the cancer cell with an extracellular matrix (ecm) composition. Also provided are methods of delivering a chemotherapeutic agent to a cancer cell by contacting a cancer cell with an extracellular matrix composition containing a chemotherapeutic agent.
Mutant ros expression in human cancer
The invention provides the identification of the presence of mutant ros protein in human cancer. In some embodiments, the mutant ros are fig-ros fusion proteins comprising part of the fig protein fused to the kinase domain of the ros kinase.
Cell Signaling Technology, Inc.
Thieno-indole moieties and methods of treating using the same
The present invention relates to a novel class of alkylating agents comprising a thieno-indole moiety linked to a dna-binding moiety, which have cytotoxic activity and are useful in treating diseases such as cancer, cellular proliferation disorders and viral infections. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising them and methods of treating diseases utilizing such compounds or the pharmaceutical composition containing them.
Nerviano Medical Sciences S.r.l.
Method for treating a cancer with a mixed ligand gold(iii) complexes as anti-cancer agents
Gold(iii) complexes with mixed ligands as anticancer agents. The gold(iii) cations are coordinated to bidentate ligands having diamino functional groups: a diaminocyclohexane ligand and a 1,3-propylenediamine ligand.
King Fahd University Of Petroleum And Minerals
Methods and compositions for vein harvest and autografting
The leading cause of graft failure is the subsequent development of intimal hyperplasia, which represents a response to injury that is thought to involve smooth muscle proliferation, migration, phenotypic modulation, and extracellular matrix (ecm) deposition. Surgical techniques typically employed for vein harvest—stretching the vein, placing the vein in low ph, solutions, and the use of toxic surgical skin markers—are shown here to cause injury.
The United States Government As Represented By The Department Of Veterans Affairs
Nanofuel internal engine
A nanofuel engine including an inventive nanofuel internal engine, whereby nuclear energy is released in the working fluid and directly converted into useful work, with the qualities of an economical advanced small modular gaseous pulsed thermal reactor. Scientific feasibility is established by studying the behavior of nuclear fuels in configurations designed to support a fission chain reaction.
Global Energy Research Associates, Llc
Method of treatment employing cardiac glycoside
A method of treatment employing cardiac glycoside is disclosed. A prognostic assay and kit and method of use thereof are provided.
Phoenix Biotechnology, Inc.
High-throughput cellular analysis using microbubble arrays
A microfabricated device and method having a substrate with an array of curvilinear cavities that is used for high throughput single cell screening. The substrate of the device is preferably fabricated in a low elastic modulus polymer such as polydimethylsiloxane.
University Of Rochester
Compositions and methods for treating cancer, inhibiting cell proliferation, and inducing cell death
Quadruplex-forming guanine-rich nucleic acid sequences are useful in compositions and methods for inhibiting cellular growth and proliferation and inducing cell death. Compositions for treating a patient are provided, including (i) a safe and effective amount of a sequence having at least 80% nucleic acid identity with a sequence selected from the group consisting of seq id no: 1, seq id no: 2, seq id no:3, seq id no: 4, seq id no: 5, seq id no: 6, seq id no: 7, seq id no: 8, seq id no: 9, seq id no:10, seq id no:11, seq id no:12 and combinations thereof, and (ii) a carrier, wherein the isolated oligonucleotide forms at least one quadruplex..
University Of Louisville Research Foundation, Cin.
Humanized anti-hla-dr antibodies
The present invention concerns compositions and methods of use of humanized anti-hla-dr antibodies. In preferred embodiments, the antibodies induce apoptosis and inhibit proliferation of lymphoma cells without inducing cdc or adcc.
Fibroin-like protein production method
A method for producing a fibroin-like protein is described. A fibroin-like protein is produced by culturing escherichia coli having a gene encoding the fibroin-like protein in a medium, inducing expression of the gene encoding the fibroin-like protein, and collecting the fibroin-like protein, wherein the cell proliferation after inducing the expression is reduced..
Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use
The presently disclosed inventive concept(s) include inhibitors of antiplasmin cleaving enzyme (apce) and fibroblast activation protein alpha (fap) which can be used in various therapies related to disorders of fibrin and α2-antiplasmin and abnormal cell proliferation. The presently disclosed inventive concept(s) also include substrates of apce and fap, which may be used, for example, in screening methods for identifying such inhibitors.
The Board Of Regents Of The University Of Oklahoma
Treatment of diabetes using g-csf
E. Exposing the patient to a stem cell proliferation agent for a third treatment period; whereby the patient's blood glucose level begins trending lower subsequent to initiation of treatment and continues to trend lower after active treatment has ended..
Hypoxia-induced mitogenic factor
We found that fizz1/relmα is inducible by hypoxia in lung. The hypoxia-upregulated expression of fizz1/relmα was located in the pulmonary vasculature, bronchial epithelial cells, and type ii pneumocytes.
The Johns Hopkins University
Treatment with opioid antagonists and mtor inhibitors
Embodiments of the invention provide methods of treating a disorder or disease characterized by cellular proliferation and migration by co-administering a synergistically effective amount of an mtor inhibitor and a μ-opioid receptor antagonist.. .
The University Of Chicago
Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, alzheimer's disease and osteoarthritis), the modulation of cellular events mediated by wnt pathway signaling, as well as genetic diseases due to mutations in wnt signaling components.
Erbb2 signaling and nerve regeneration
Use of an inhibitor of the erbb2 receptor for treatment or repair of nerves and/or nerve tissues is provided. The inhibitor includes an antibody, in particular, a monoclonal antibody, for example, herceptin.
The Hospital For Sick Children